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Insect cell expression of the HIV-1 Gag precursor protein by recombinant baculoviruses results in the assembly and
budding of noninfectious virus-like particles (VLPs). The VLPs resemble immature virus in ultrastructural morphology and
can be purified by conventional retroviral techniques. The virus-like appearance of the particles suggested that they could
be used to package additional peptides. The retroviral frameshift mechanism was used to translate the pol gene products
by expressing additional genetic information as chimeric Gag–Pol fusion proteins. Sequences encoding the carboxyl 65%
of the HIV-1 surface glycoprotein (gp120, SU) were inserted into the Gag–Pol reading frame immediately downstream of
the Gag stop codon. The assembly and budding of large quantities of Gag and chimeric Gag–SU VLPs were observed by
standard transmission electron microscopy. The presence of gp120 epitopes in the Gag–SU VLPs was confirmed by
immunoelectron microscopy and Western blot analysis using monoclonal anti-gp120 antibodies. Mice inoculated with the
Gag–SU pseudovirions developed cytotoxic lymphocyte responses to both HIV-1 Gag and Env epitopes yet humoral immune
responses only to Gag epitopes. The chimeric Gag–SU particles may have applications as vaccines or immunotherapeutic
treatments for HIV-1 infection. In addition, the frameshift mechanism can be applied to the packaging of other viral or
cellular proteins. q 1997 Academic Press
INTRODUCTION infectious virus-like particles (VLPs) for the production of
effective HIV vaccines or postinfection therapies (Griffiths
A typical course of infection with the human immuno-
et al., 1991; Luo et al., 1992; Adams et al., 1993; Tobin
deficiency virus type-1 (HIV-1) is characterized by a short
et al., 1996b; Wagner et al., 1996a).
acute phase in which rapid replication causes a high
Expression of retroviral Gag precursor proteins in eu-viral burden and a longer subacute stage in which the
karyotic systems can result in the assembly and buddingperipheral blood viral burden is reduced initially and im-
of VLPs that resemble immature lentivirus particles (Ad-munological functions slowly decline (Ho et al., 1989;
ams et al., 1987; Gheysen et al., 1989; Karacostas et al.,Daar et al., 1991; Michael and Burke, 1991; Koup et al.,
1989; Delchambre et al., 1989; Rasmussen et al., 1990;1994; Graziosi et al., 1993; Levy, 1993a; Pantaleo et al.,
Luo et al., 1990; Morikawa et al., 1991; Tobin et al., 1995).1994). A small percentage of HIV-infected individuals ap-
The VLPs lack the viral genome and pol gene productspear to have an extremely low viral burden and maintain
and are therefore nonreplicating. Animal and human in-normal numbers of CD4/ T cells for an extended length
oculation studies have shown that Gag VLPs are highlyof time. Recent studies have indicated that a reduction
immunogenic and, therefore, may be useful for vaccinein virus burden due to the development of strong CTL
or immunotherapeutic applications (Gheysen et al., 1989;responses and, perhaps, low levels of neutralizing anti-
Luo et al., 1990; Adams et al., 1993; Wagner et al., 1994,bodies may be a major factor in the continued health of
1996a,b; Tobin et al., 1995; Weber et al., 1995; Layton etsome long-term survivors (Borrow et al., 1994; Cao et al.,
al., 1996). To increase the epitope repertoire of the Gag1995; Ferbas et al., 1995; Klein et al., 1995; Rinaldo et
VLPs, several strategies have been devised to packageal., 1995; Harrer et al., 1996; Mellors et al., 1996). These
domains of the Env glycoprotein, gp120 (SU). Coexpres-data suggest that the administration of antigenic material
sion of HIV or SIV Gag and Env precursor proteins inmay be of protective or therapeutic value. Therefore, we,
insect cells can result in the incorporation of the Envand others, have investigated strategies to engineer non-
precursor into the particle membrane as determined by
immunoblotting and immunoelectron microscopy (Kraus-The U.S. Government’s right to retain a nonexclusive royalty-free
slich et al., 1993; Yamshchikov et al., 1995; Tobin et al.,license in and to the copyright covering this paper, for governmental
purposes, is acknowledged. 1996a). However, some difficulties have been encoun-
1 To whom correspondence and reprint requests should be ad- tered in the retention of the Env glycoprotein during rigor-
dressed at Bldg. 560, P.O. Box B, Frederick, MD 21702. Fax: (301) 846- ous purification procedures (Tobin et al., 1996a). In a5427. E-mail: tobin@mail.ncifcrf.gov.
second strategy, viral gp120 epitopes have been engi-2 Current address: Genovo, Inc., P.O. Box 42884, Philadelphia, PA
19101. neered as internal insertions into the Gag precursor. If
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FIG. 1. Gene structure of HIV Gag and Gag-fs-SU reading frames. Diagram of HIV Gag (A) and Gag-fs-SU (B) reading frames inserted into
recombinant baculoviruses for the generation of Gag and Gag–SU VLPs. Diagrams show positions of the polyhedron promoter, the translational
start codon for Gag and Gag– SU protein synthesis, and the expected amino acid translations of the two constructs. B details the position and
translation of the ribosomal frameshift used to synthesize the Gag–SU fusion protein. Numbering from the N-terminal Met codon, the Env fragment
includes residues 255 through 527 (GIR through GAA).
the insertions are made into regions of the Gag precursor carboxy 65% of HIV-1mn gp120 and the first 14 residues
of the transmembrane glycoproteins were amplified fromthat are not critical to particle formation, large quantities
of chimeric VLPs can be produced (Luo et al., 1992; pHIV-1mn-st1 (Lori et al., 1992) with primers 5* CCGGTT-
AATTAATGGAATTAGGCCAGTAGTATCAACT (nt 7000 toWagner et al., 1994, 1996a, 1996b; Griffiths et al., 1993).
The maximum permissible size of the insertion is not 7024, including a PacI RE site and an additional nucleotide
to put the SU portion in frame with Gag–Pol) and 5* GCA-clear as the above studies have been restricted to epi-
topes less than 100 amino acids in length. A third strat- TGTTTAAACTGCTGCTCCTAAGAACCCAAGGAA (nt 7796
to 7819, including a PmeI RE site). The cloned gene frag-egy, developed during the present study, takes advan-
tage of the ribosomal frameshifting signals located near ment is expected to encode the HIVmn Env residues 255
through 527 (GIR through GAA). The amplified fragmentsthe 3* end of the Gag open reading frame to package
larger portions of the HIV SU protein. Retroviruses ex- were cloned separately into pCRII (Invitrogen) to generate
pCR-Hgag and pCR-HSU, respectively. All plasmids gener-press both the Gag and the Gag–Pol precursor proteins
from the full-length mRNA. During the translation of the ated by PCR methods were confirmed by DNA sequence
analysis. The SU fragment was excised from pCR-HSU byGag precursor protein, the ribosome encounters putative
frameshifting signals which include a hexanucleotide se- digestion with PacI and PmeI and cloned into pCR-Hgag
3* of the Gag stop codon such that the SU codons werequence, a stem–loop structure, and a pseudoknot struc-
ture (Parkin et al., 1992). At a frequency of between ap- in the Gag–Pol reading frame. The Gag–SU cassette was
excised with EcoRI and PmeI and cloned into the baculovi-proximately 1 and 5%, the frameshift signals cause a 01
nt ribosomal frameshift that results in the translation of rus transfer vector pBacPAK4 (Clontech) to generate pBac-
Hgag-SU. AcMNPV-Hgag-SU was derived by cotransfec-the Gag–Pol precursor protein. We present the results
of our studies in which a major fragment of the gp120 tion of pBac-Hgag-SU and AcMNPV genomic DNA into Sf-
9 cells using standard baculovirus technologies (Tobin etprotein was expressed in the Gag–Pol reading frame as
a chimeric Gag–SU frameshift fusion protein. The Gag – al., 1995; Summers and Smith, 1987).
SU VLPs were injected into mice for characterization of
Insect cell culture and baculovirus infectionhumoral and cellular immune responses.
Spodoptera frugiperda Sf-9 insect cells were propa-
MATERIALS AND METHODS
gated in Grace’s medium supplemented with 7% fetal
bovine serum (FBS) and 0.33% each of lactalbumin hy-Genetic engineering of recombinant baculoviruses
drolysate and yeastolate. For production of VLPs, cells
Generation of the recombinant baculovirus that directs
were infected with recombinant baculoviruses at a multi-
the expression of the HIV-1 gag gene (AcMNPV-Hgag) has
plicity of infection of 5 plaque-forming units per cell.
been described (Tobin et al., 1996a). For the generation of
AcMNPV-Hgag-SU (Fig. 1), DNA sequences encoding the Electron microscopy
entire HIV-1 hxb2 Gag precursor were amplified from
pHXB2 (Ratner et al., 1987) using the polymerase chain At 2 days postinfection, cell cultures were removed
from the flasks by gentle scraping, pelleted at 150 greaction with primers 5* ACTAGCGGAGGCTAGAAGGAG-
AGAG (nt 765 to 789) and 5* GTTTAAACGTTAACTTAATTA- for 5 min, and fixed and embedded for either standard
transmission electron microscopy (TEM) or postembed-CTTGCTACGCGTTAGAGCTTCCTTTAGTTGCCCCCC (nt
2297 to 2320). The reverse oligo encoded restriction endo- ding immunoelectron microscopy (IEM) as previously de-
scribed (Tobin et al., 1996a). For IEM, 60- to 70-nm thinnuclease (RE) sites MluI, PacI, HpaI, and PmeI to facilitate
successive sequence insertions. Sequences encoding the sections were cut, mounted on a nickel grid, incubated
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in a 1:10 dilution of normal goat serum in 50 mM Tris – were processed after six injections. In Experiment 2,
mice were injected once with either 2 or 20 mg VLPs inHCl, pH 8.2, 250 mM NaCl, and 0.1% BSA, and reacted
with 1:20 dilutions of mouse monoclonal anti-p17 (D3D9) PBS. Three weeks after the final immunization of both
experiments, serum samples were collected and spleensor anti-gp120 (P8A9) antibodies (obtained from Drs. S.
Nigida and L. Arthur, AIDS Vaccine Program, National were removed for immunological assays.
Cancer Institute). The sections were washed, incubated
Immunological assaysin 1:100 dilutions of 10-nm colloidal gold-conjugated sec-
ondary antibody for 1 hr, and rewashed. The thin sections Serum samples from immunized mice were tested for
were counterstained with uranyl acetate and lead citrate, HIV Gag and Env reactivity by standard immunoblot tech-
stabilized by carbon evaporation, observed, and photo- niques (Coligan et al., 1994). Briefly, either sucrose gradi-
graphed with a Hitachi H-7000 electron microscope oper- ent-purified Gag VLPs or affinity-purified native gp120
ated at 75 kV. (obtained from J. Bess and L. Arthur, AIDS Vaccine Pro-
gram, National Cancer Institute) was electrophoresed
Purification and protein analysis of virus-like particles and transferred to PVDF membranes. The membranes
were cut into 5-mm strips, reacted with mouse sera fromFour days following infection, VLPs were purified from
inoculated animals, diluted 1:500 (Gag strips) or 1:100Sf-9 culture supernatants based upon their particulate
(gp120 strips), and alkaline phosphatase-conjugatednature and buoyant density as previously described
goat anti-mouse antibody diluted 1:5000 or 1:1000, re-(Gheysen et al., 1989; Rasmussen et al., 1990; Tobin et
spectively. Bound antibodies were visualized by chemilu-al., 1995). Briefly, culture supernatants were clarified at
minescence and autoradiography.2000 g for 15 min; precipitated in 2.3% NaCl and 8% (w/
Splenic cells were assayed for cell-mediated lysis ofv) polyethylene glycol; resuspended in 10 mM Tris–HCl,
P815 mastoblastoma cells infected with recombinantpH 8.0, 1 mM EDTA, and 150 mM NaCl (TNE); and centri-
Gag or Env vaccinia viruses (obtained from P. Earl andfuged through 10–60% (w/w) sucrose gradients in TNE
B. Moss, National Institutes of Health) as describedfor 3 hr at 85,000 g. The material that sedimented at 1.16
(Walker et al., 1987). Single-cell suspensions of spleensg/ml was removed from the gradients, diluted in three
were cultured for 5 days in RPMI medium supplementedvolumes of TNE, repelleted for 1.5 hr at 85,000 g, and
with 10% (v/v) FBS, 0.01% (w/v) purified Gag VLP, 0.001%resuspended in TNE. Total protein concentration of the
(w/v) gp120, and 10 iu/ml human IL-2 (Cetus) to propa-purified material was estimated using the Bradford dye-
gate effector T cells. P815 cells were infected at an m.o.i.binding method (Bio-Rad Laboratories, Inc.) and compari-
of 5 PFU/ml with either Gag- or Env-vaccinia viruses 17son to known concentrations of bovine serum albumin.
hr prior to the start of the lysis assay. Effector and targetApproximately 5 mg of purified VLPs was obtained from
cells were washed twice in chemically defined, serum-1 L of insect cell culture supernatant.
free medium (Opti-MEM; Life Technologies) at the startProteins contained within the VLP preparations were
of the assay. Assays consisted of triplicate wells con-resolved on denaturing polyacrylamide gels and trans-
taining 1 1 104 target cells mixed with between 3 1 104ferred to PVDF membranes for immunoblotting using
and 1 1 106 effector cells in a total volume of 0.2 mlstandard techniques (Coligan et al., 1994). Immobilized
Opti-MEM. Negative and positive lysis control wells con-proteins were reacted with 1:5000 dilutions of mouse
tained no effector cells and 0.1% Triton X-100, respec-monoclonal anti-p17 (D3D9) and anti-gp120 (P8A9),
tively. Four hours after the start of the assay, 0.1 mlwashed, and reacted with horseradish peroxidase-conju-
culture supernatant was carefully withdrawn and thegated goat anti-mouse IgG antibody. Bound antibody was
amount of lactose dehydrogenase was quantitated usingvisualized by chemiluminescence (Amersham) and expo-
an enzymatic tetrazolium-based assay read at 690 nmsure to XAR-5 film (Kodak).
(LDH assay; Boehringer Mannheim Biochemicals). The
mean absorbance values of the negative lysis controlsImmunization of mice
were subtracted from the mean values of the triplicate
Two groups of female Balb/c mice, 6 to 8 weeks of experimental wells. The percentage of lysis was ex-
age, were inoculated by subcutaneous injection of either pressed as the ratio of the absorbance values of the
HIV Gag or Gag–SU particles in two independent experi- subtracted experimental wells to the detergent-lysed (to-
ments. In Experiment 1, mice were inoculated with 20 tal lysis) wells. Percentage of lysis data were graphed
mg VLPs suspended in 0.2 ml volume of either complete for individual mouse splenocyte cultures in Experiment
Freund’s adjuvant or phosphate-buffered saline (PBS). 1 and for splenocyte pools in Experiment 2.
Boosts containing the same quantity of antigen were
done at 3-week intervals in either incomplete Freund’s RESULTS
adjuvant or PBS, respectively. Serum samples were pre-
Incorporation of gp120 epitopes in budding VLPspared from the mice at each inoculation. The spleens
from approximately 50% of the mice were removed for Sf-9 cells infected with recombinant baculoviruses
were examined by TEM and IEM. Standard TEM analysisanalysis after four injections and the remainder of mice
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and Gag–SU VLPs (Figs. 2C and 2D). In contrast, labeling
with anti-gp120 antibody resulted in the labeling of only
the Gag–SU VLPs (Figs. 2E and 2F).
Chimeric VLPs package Gag–SU fusions
Based upon the DNA sequences of the baculovirus
constructs, the molecular masses of the Gag and Gag–
SU proteins were calculated to be approximately 55,930
and 89,208 daltons for the 500- and 798-residue proteins,
respectively. Proteins contained in preparations of su-
crose gradient-purified VLPs were resolved by denatur-
ing PAGE and analyzed by Western blotting. Membrane
strips containing 0.15 mg Gag or 1.5 mg Gag–SU VLPs
were reacted with anti-17Gag and anti-gp120 monoclonal
antibodies (Fig. 3). A protein species of approximately 55
kDa present in each VLP preparation was detected by
the anti-p17Gag but not the anti-gp120 antibody (lanes 3
and 6). In contrast, both antibodies reacted with a protein
of approximately 90 kDa present in the Gag–SU but not
the Gag VLP sample (lanes 2, 3, 5, and 6).
VLPs elicit a humoral response to Gag but not Env
epitopes
To study the humoral antigenicity of the HIV VLPs,
female Balb/c mice were inoculated repeatedly with su-
crose gradient-purified Gag and Gag–SU as described
FIG. 2. Electron microscopic analysis of HIV Gag and Gag–SU VLPs.
Thin section of Sf-9 cells infected with either AcMNPV-Hgag (A, C, E)
or AcMNPV-Hgag-SU baculoviruses (B, D, F). A and B were generated
by standard transmission electron microscopy and C–F by postembed-
ded immunoelectron microscopy using mouse monoclonal anti-p17Gag
(C and D) or anti-gp120 (E and F) antibodies. Bound mouse antibodies
were detected with colloidal gold-conjugated goat anti-mouse antibody.
The magnification size bar represents 100 nm.
of embedded cells which had been infected with either
AcMNPV-Hgag or AcMNPC-Hgag-SU revealed large
numbers of VLPs budding and budded from the plasma
membrane (Figs. 2A and 2B). As per previous reports
(Tobin et al., 1996b; Gheysen et al., 1989), the hollow
sphere appearance of the HIV Gag VLPs resembled im-
mature lentivirus particles. The Gag and Gag–SU VLPs
were indistinguishable from each other by conventional
TEM. Consistent with the engineering of the SU to the
FIG. 3. Immunoblot analysis of HIV Gag and Gag–SU VLPs. Proteinscarboxyl portion of the Gag precursor, no glycoprotein
contained in sucrose-purified HIV Gag (lanes 1–3) and Gag–SU (lanes
projections were seen on the surface of the VLPs. 4–6) VLPs were electrophoresed in denaturing gels containing 10%
For post-embedded IEM analysis, thin sections of insect polyacrylamide and transferred to PTFE membranes. The membranes
were cut into strips and reacted with unimmunized mouse serum (lanescells infected with either AcMNPV-Hgag or AcMNPV-
1 and 4), mouse monoclonal anti-gp120 3F5 antibody (1:1000; lanes 2Hgag-SU were reacted with mouse anti-Gag and anti-SU
and 5), or anti-p17Gag 3D9 antibody (1:2000; lanes 3 and 6). Boundmonoclonal antibodies followed by colloidal gold-conju-
mouse antibodies were detected with alkaline phosphatase-conju-
gated goat anti-mouse antibody. Labeling with anti-p17Gag gated goat anti-mouse antibodies and visualized by enhanced chemilu-
antibody resulted in the deposition of numerous colloidal minescence. The numbers to the left show the relative migrations of
protein molecular mass markers.gold particles on the surface of budding and budded Gag
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tions of HIV Gag–SU VLPs were stimulated with antigen
in vitro and assayed for lysis of P815 cells expressing
HIVmn gp160 (Fig. 5A). Lysis of target cells at varying
effector:target cell ratios was expressed as the percent-
age of total target cell lysis by comparison to detergent-
lysed control wells. Data points represented by open
symbols and dashed line were derived from mice inocu-
lated with Gag–SU in Freund’s adjuvant; solid symbols
and lines were derived from mice inoculated with Gag–
SU in PBS. Each line in Fig. 5 represents the percentage
of target cell lysis of an individual mouse. The lysis data
in Fig. 5A indicates that each mouse developed measur-
able Env-specific lysis and that the level of lysis was
relatively high at 1:100 and 1:50 ratios regardless of the
presence of adjuvant. Splenocytes from mice that re-
ceived an additional two boosts of Gag–SU were as-
sayed for lysis of Env and Gag targets 6 weeks later
FIG. 4. Immunoblot analyses of sera from mice inoculated with HIV (Figs. 5B and 5C). All data in Fig. 5B were derived from
Gag and Gag–SU VLPs. Proteins contained in sucrose-purified HIV mice inoculated with Gag–SU. In Fig. 5C, three lines
Gag VLPs (A) and affinity-purified native gp120 (B) were electropho-
were derived from mice inoculated with Gag–SU andresed in denaturing gels containing 10% polyacrylamide and transferred
two were from mice inoculated with Gag VLPs. Due toto PTFE membranes. The membranes were cut into strips and reacted
with sera from mice inoculated with Gag VLP in PBS (lanes 1), Gag limiting numbers of effector cells, not all splenocyte cul-
VLP in Freund’s adjuvant (lanes 2), Gag–SU VLP in PBS (lanes 3), or tures were tested for both Gag and Env target lysis. Al-
Gag–SU VLPs in Freund’s adjuvant (lanes 4). Control lanes were re- though two mice appeared to generate anti-Env CTL re-
acted with normal mouse sera (lanes A6 and B5), mouse monoclonal
sponses comparable to those shown in Fig. 5A, threeanti-p17Gag 3D9 antibody (lane A5), or mouse monoclonal anti-gp120
mice exhibited weaker responses (Fig. 5B). Splenocytes3F5 antibody (lane B6). Bound mouse antibodies were detected with
alkaline phosphatase-conjugated goat anti-mouse antibodies and visu- from Gag VLP-inoculated mice lysed Gag targets effi-
alized by enhanced chemiluminescence. The numbers to the left show ciently at effector:target ratios of 50 and 100 (Fig. 5C).
the relative migrations of protein molecular mass markers.
Splenocytes from Gag–SU-inoculated mice showed a
wide range of anti-Gag lysis as one culture lysed the
targets well at high ratios while two others showed mar-under Materials and Methods. Serum samples from the
ginal activity. It should be noted that the splenocyte cul-immunized mice were examined for reactivity to the HIV
tures that produced the lowest level of Gag and Env CTLGag precursor using Western blot strips containing 0.25
activities in Figs. 5B and 5C also had lower cell viabilitiesmg sucrose gradient-purified Gag VLP (Fig. 4A). Sera col-
compared to the cultures that demonstrated higher CTLlected after the second Gag or Gag–SU VLP immuniza-
responses. The presence of Freund’s adjuvant in the in-tion reacted with Pr55Gag (Fig. 4A, lanes 1–4) as did sera
ocula did not appear to be a factor in the CTL activitiesfrom later bleeds (data not shown). The Gag reactivity of
that were generated.sera from mice inoculated with VLPs in PBS (lanes 1 and
3) appeared similar to that of sera from mice inoculated To assess the effect of VLP concentration on the gen-
with VLPs in Freund’s adjuvant (lanes 2 and 4). Western eration of HIV-specific CTL responses, four groups of
blot strips containing 0.5 mg gp120 purified from HIV-1- four female Balb/c mice were inoculated once with either
infected human cells were used to test the generation 2 or 20 mg of Gag or Gag–SU VLPs in 0.2 ml PBS. An
of anti-SU antibodies in mice inoculated with Gag–SU additional group was inoculated with PBS as a negative
VLPs. Serum samples that were drawn after multiple in- control. Three weeks following the inoculation, spleno-
oculations of Gag–SU VLPs failed to react to native cyte cultures from the five groups were pooled, stimu-
gp120 (Fig. 4B, lanes 3 and 4). The presence of adjuvant lated in vitro, and tested for lysis of Gag and Env target
in the inocula (lane 4) did not affect stimulation of anti- cells. Splenocytes from mice immunized with Gag–SU
gp120 antibodies. VLPs lysed both Gag and Env targets (Fig. 6). The correla-
tions between percentage of lysis and CTL effector:target
Chimeric VLPs stimulate CTL responses to Gag and cell ratios were approximately linear between ratios of
Env epitopes 25 to 100. At the highest ratios, mice that were inoculated
with 2 mg of antigen generated greater CTL activitiesTo study the stimulation of Gag- and Env-specific cellu-
than those inoculated with 20 mg. Splenocytes from micelar immune responses, female Balb/c mice were inocu-
inoculated with Gag VLPs demonstrated patterns of Gag-lated with sucrose gradient-purified VLPs in two indepen-
specific target lysis similar to those of the mice inocu-dent experiments as described under Materials and
Methods. Splenocytes from mice that received four injec- lated with Gag–SU (Fig. 6A). In addition, some apparently
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FIG. 5. CTL responses of splenocytes from mice inoculated multiple times with HIV Gag or Gag–SU VLPs. Female Balb/c mice were inoculated
with 20 mg HIV Gag or Gag–SU VLPs in either PBS (solid lines and filled symbols) or Freund’s adjuvant (dashed lines and open symbols) at 3-
week intervals. Splenocyte cultures were prepared after either (A) 4 or (B and C) 6 injections, antigen-stimulated in vitro, and assayed in triplicate
for lysis of PA815 cells expressing either (A and B) HIV Env or (C) Gag precursor proteins by release of lactose dehydrogenase. All data in A and
B were derived from mice inoculated with Gag–SU VLPs. Target cell lysis at varying ratios of effector to target cells was expressed as the percentage
of total lysis from detergent-disrupted target cells. Each line was derived from the mean percentage lysis values derived from CLT assays of an
individual mouse. In C, lysis values represented by the symbols L, l, and c were derived from mice inoculated with Gag–SU VLPs, and symbols
l and s from mice inoculated with Gag VLPs. Lines sharing the same symbol between B and C (L, l, c) were derived from aliquots of splenocytes
cultured from the same mice.
nonspecific cell lysis was observed from mice inoculated Multiple inoculation of mice with either Gag or Gag –
SU VLPs resulted in strong humoral responses to Gagwith 20 mg but not 2 mg of Gag VLPs (Fig. 6B).
epitopes (Fig. 4A) but not to gp120 epitopes (Fig. 4B).
In contrast, CTL responses to both Gag and SU epitopesDISCUSSION
were seen in mice given a single 2-mg inoculation of
The expression of the HIV Gag precursor protein in
Gag – SU VLPs (Fig. 6). Previous reports have suggested
insect cells resulted in the assembly and budding of
that the inclusion of adjuvants in VLP inocula causes a
numerous VLPs. The coexpression of a large portion of
shift toward a predominant humoral response and away
the SU protein in the Gag–Pol reading frame resulted in
from a CTL response (Layton et al., 1993; Wagner et al.,
the production of VLPs that packaged the Gag–SU fusion
1996a). This phenomenon was not seen in our experi-
protein with Pr55Gag. The presence of the SU fragment
ments; mice that received multiple injections of VLPs in
in the VLPs was confirmed by postembedded IEM analy-
either Freund’s adjuvant or PBS alone developed similar
sis of insect cells infected with AcMNPV-Hgag-SU. In
CTL responses (Fig. 5). However, the present data sug-
addition, immunoblot analyses of purified Hgag-SU VLPs
gest that the addition of adjuvant is unnecessary and
indicated that a protein of the predicted mobility for the
can be avoided. We hypothesize that the particulate
Gag–SU fusion protein contained both Gag and SU epi-
topes. Although Western blots are semiquantitative at
best, a comparison of the relative intensities of the Pr55
and the Gag–SU protein bands in lane 6 of Fig. 3, and
other blots not shown, suggests that the ratio of the two
proteins in the chimeric particles is approximately 1:100.
This ratio is consistent with previously reported frequen-
cies of translational frameshifting (Parkin et al., 1992). In
previous studies, relatively large fusion partners were
expressed in frame at the C-terminus of the Gag precur-
sor (Tobin et al., 1996b). Because these in-frame fusion
proteins failed to assemble and bud efficiently from the
plasma membrane, it is likely that a reduced molar ratio
of fusion protein to Gag precursor permits efficient parti- FIG. 6. CTL responses of splenocytes from mice inoculated once
cle formation, and a large fusion partner on the C-termi- with HIV Gag or Gag–SU VLPs. Female Balb/c mice were inoculated
once with 20 mg HIV Gag (m), 2 mg Gag (n), 20 mg Gag–SU (l), 2 mgnus of each Gag precursor molecule may interfere with
Gag–SU VLPs in PBS (s), or PBS alone (h). Splenocyte cultures wereparticle formation. Although other groups have con-
prepared 3 weeks after inoculation, antigen-stimulated in vitro, andstructed chimeric HIV Gag VLPs containing short, in-
assayed for lysis of PA815 cells expressing either (A) HIV Env or (B)
frame gp120 epitopes (Luo et al., 1992; Peifang et al., Gag precursor proteins by release of lactose dehydrogenase. Target
1994; Wagner et al., 1996a), frameshift fusion proteins cell lysis at varying ratios of effector to target cells was expressed as
the percentage of total lysis from detergent-disrupted target cells.appear to accept larger peptide insertions.
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nature of the VLPs may have caused the mice to develop tinue to guide the development of effective vaccines and
postinfection immunotherapies.CTL but not antibody responses to SU epitopes. Other
studies have shown that particulate antigens are power-
ful inducers of CTL responses (Layton et al., 1996; Mar- ACKNOWLEDGMENTS
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